ELOOP SRL

Their core work

ELOOP SRL is a Naples-based technology SME working at the intersection of advanced material processing and bioactive compound development. In the REMADYL project, they contributed to a continuous extrusion-based process for removing hazardous legacy substances — lead, phthalates, and DEHP — from post-consumer PVC, enabling genuine circular recycling of contaminated plastic waste. In the Algae4IBD project, their focus shifted to the development and processing of algae-derived biocompounds targeting inflammatory bowel disease and microbiome health. Across both projects, their practical value appears to lie in process engineering and the transformation of raw biological or polymer inputs into functional outputs — whether a clean recyclate or a therapeutic food ingredient.

What they specialise in

How they've shifted over time

ELOOP's H2020 trajectory shows a clear pivot: their first project (2019) was squarely in industrial circular economy — cleaning toxic plastics through extrusion chemistry. Their second project (2021) entered an entirely different domain — marine biology, gut immunology, and functional food. What connects the two is likely a core competency in transformation processes: taking a contaminated or raw material and engineering it into something safe and usable. The direction of travel is unmistakably toward bioactive ingredients and health applications, moving away from the materials/environment space.

ELOOP appears to be repositioning from industrial materials processing toward bioactive food and health ingredients, with algae-based compounds and microbiome applications likely to define their next collaboration profile.

How they like to work

ELOOP has participated in all projects as a consortium partner, never as coordinator, suggesting they function as a specialist contributor rather than a project architect. Their consortium exposure is disproportionately large for a two-project portfolio — 37 unique partners across 13 countries — indicating they joined well-networked, multi-partner RIA consortia rather than small bilateral arrangements. This makes them experienced at operating inside large European projects, even if their organizational leadership profile is limited.

Despite only two projects, ELOOP has built a surprisingly broad network of 37 unique partners spanning 13 countries, reflecting the multi-actor composition of the RIA consortia they joined. Their collaboration footprint is European in scope, with no visible regional concentration beyond their Italian base.

What sets them apart

ELOOP occupies an unusual dual position: they have hands-on experience in both industrial polymer remediation and algae-based therapeutic nutrition — two sectors that rarely share the same organizational profile. For a consortium builder, this means ELOOP brings applied process engineering credibility to projects that need a partner who can move from bench-scale biology to functional product. As a Neapolitan SME, they also offer geographic diversity within the Italian research ecosystem, which is dominated by northern institutions.

Highlights from their portfolio

• REMADYL
  The larger of the two projects by EC funding (EUR 350,500), targeting a commercially important problem — recovering usable PVC from contaminated waste — through a continuous industrial extrusion process, with direct relevance to European plastics regulation and circular economy policy.
• Algae4IBD
  A long-horizon project (2021–2026) in a high-growth area combining marine biotechnology, microbiome science, and functional food, signalling ELOOP's strategic bet on nature-based health solutions as their future positioning.